Testing Gene PilotLX With Latinx Cancer Patients

Launched by FOX CHASE CANCER CENTER · Jun 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a tool called Gene PilotLX, which helps Latinx cancer patients better understand their hereditary risk information from a specific genetic test known as tumor genomic profiling. The goal is to see if using this electronic health tool can help patients make more informed decisions about their cancer treatment options. The trial will take place at four cancer centers, and it is not yet open for participants.

To be eligible for this trial, patients must identify as Latinx, have been diagnosed with solid tumor cancers (not blood cancers like leukemia or lymphoma), and be able to read or speak either English or Spanish. Participants will be asked to provide informed consent, meaning they understand what the trial involves and agree to take part. If eligible, participants can expect to use the Gene PilotLX tool to learn more about their genetic test results and how these results might affect their treatment choices.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Self-identified Latinx patients who:
• • 1. diagnosed with solid tumor cancers
• • 2. speak/read English or Spanish;
• • 3. can provide informed consent.
• Exclusion Criteria:
• • Patients with hematologic/liquid cancers (leukemia, lymphoma, multiple myeloma, etc.)